Azvudine

Azvudine (RO-0622) is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and HCV. Azvudine exerts highly potent inhibition on HIV-1 (EC50s ranging from 0.03 to 6.92 nM) and HIV-2 (EC50s ranging from 0.018 to 0.025 nM) . Azvudine inhibits NRTI-resistant viral strains[1]. Azvudine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Product Specifications

CAS Number

[1011529-10-4]

Product Name Alternative

RO-0622; FNC

UNSPSC

12352005

Target

HBV; HCV; HIV; Reverse Transcriptase

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/azvudine.html

Purity

99.79

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

Smiles

O[C@@H]1[C@](CO)(N=[N+]=[N-])O[C@@H](N2C(N=C(N)C=C2)=O)[C@H]1F

Molecular Formula

C9H11FN6O4

Molecular Weight

286.22

References & Citations

[1]Wang RR, et al. Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. PLoS One. 2014 Aug 21;9 (8) :e105617.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

HIV-1; HIV-2

Citation 01

Acta Pharm Sin B. 2024 Mar 30.|Antiviral Res. 2025 Jan 16:235:106081.|NAR Mol Med. 2025 Aug 11.|Signal Transduct Target Ther. 2025 Jan 17;10 (1) :30.|Biomed Pharmacother. 2025 May 27:188:118215.